Viking Therapeutics' Weight Loss Drug Shows Promise in Early Trial

The company's stock surges as it plans Phase 2 trial for its oral obesity treatment, VK2735.

Viking Therapeutics' experimental weight loss drug, VK2735, shows promising results in a Phase 1 study, leading to a significant stock price increase.
The oral tablet version of VK2735 demonstrated a dose-dependent reduction in average body weight of up to 5.3% over 28 days, with minimal gastrointestinal side effects reported.
Viking plans to initiate a Phase 2 trial of VK2735 in the second half of 2024, aiming to explore longer treatment durations and potentially higher doses.
The weight loss drug market is becoming increasingly competitive, with Viking Therapeutics vying against major players like Novo Nordisk and Eli Lilly.
Analysts predict a significant market potential for GLP-1 drugs, with potential boosts to GDP and healthcare cost savings due to improved workforce productivity and reduced obesity-related health issues.